cyadox and Body-Weight

cyadox has been researched along with Body-Weight* in 4 studies

Other Studies

4 other study(ies) available for cyadox and Body-Weight

ArticleYear
Assessment of thirteen-week subchronic oral toxicity of cyadox in Beagle dogs.
    Regulatory toxicology and pharmacology : RTP, 2015, Volume: 73, Issue:2

    Cyadox (2-formylquinoxaline-N(1),N(4)-dioxide cyanocetylhydrazone) is a new antimicrobial agent and growth-promoter to be used in food-producing animals. Although its toxicity has been clearly documented in rodents, no study is available in non-rodent animals. Therefore, we studied the subchronic effects of cyadox in Beagle dogs to provide additional information with which to establish safety criteria for human exposure. For this purpose, 36 Beagle dogs, 18 males and 18 females, were divided into four groups and fed diets containing 0, 100, 450 and 2500 mg/kg of cyadox, respectively, for 13 weeks. It was found that there were no significant changes among the examined parameters, except for an increase in the level of serum potassium (K(+)) in 2500 mg/kg cyadox group in males at week 13 of the study. However, the K(+) level returned to normal during the recovery period. In conclusion, cyadox showed slight effects in Beagle dogs in the subchronic oral toxicity study. The no-observed-adverse-effect level of cyadox was considered to be 450 mg/kg diet, which equates to approximately 15.3-15.4 mg/kg b.w./day. The study provided subchronic effects of cyadox in Beagle dogs, suggesting that cyadox might present mild toxicity in non-rodents.

    Topics: Administration, Oral; Animals; Body Weight; Dogs; Eating; Female; Male; No-Observed-Adverse-Effect Level; Organ Size; Quinoxalines; Time Factors; Toxicity Tests, Subchronic

2015
A chronic toxicity study of cyadox in Wistar rats.
    Regulatory toxicology and pharmacology : RTP, 2011, Volume: 59, Issue:2

    To investigate the chronic toxicity of cyadox, a growth promoting agent, five groups of Wistar rats (30 rats/group/sex) were fed with the diets containing cyadox (0, 100, 400 and 2000 mg/kg) or olaquindox (400 mg/kg) for 78weeks. There were significant decreases in body weights in both genders during most of the study period in 2000 mg/kg cyadox and 400 mg/kg olaquindox rats. Significant decreases in serum alkaline aminotransferase in the 2000 mg/kg cyadox rats at weeks 26, 52 and 78 were observed. Relative weights of liver and kidney were significantly increased in 2000 mg/kg cyadox and 400 mg/kg olaquindox rats at weeks 26, 52 and 78. A significant increase in relative brain and heart weights in 2000 mg/kg cyadox males was observed. The histopathological examinations revealed that 2000 mg/kg cyadox diet or 400 mg/kg olaquindox diet could induce proliferation of bile canaliculi in the portal area of liver and swelling and fatty degeneration of the proximal renal tubular epithelial cells in kidneys. In conclusion, the target organs of cyadox for rats were liver and kidney. The no-observed-adverse-effect level of cyadox in this study was estimated to be 400 mg/kg diet.

    Topics: Animals; Body Weight; Eating; Female; Kidney; Liver; Male; No-Observed-Adverse-Effect Level; Organ Size; Quinoxalines; Random Allocation; Rats; Rats, Wistar; Toxicity Tests, Chronic; Transaminases

2011
Two generation reproduction and teratogenicity studies of feeding cyadox in Wistar rats.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2011, Volume: 49, Issue:5

    To investigate the teratogenic potential and reproductive toxicity of cyadox, a growth promoting agent, Wistar rats (F(0)) were fed with diets containing cyadox (0, 50, 150 and 2500 mg/kg) or olaquindox (150 mg/kg), approximately equivalent to cyadox 5, 15, 250 or olaquindox 15 mg/kg b.w./day across two generations. Half of the pregnant rats (F(0), F(1b)) were subjected to caesarean section on gestational day 20 for teratogenic examination and the other half produced pups F(1a) and F(2a), respectively. At the 250 mg/kg b.w./day cyadox group, body weights of F(1b) pregnant rats and F(2a) on day 21 after birth decreased; fetal body lengths and tail lengths decreased; the number of fetal resorptions increased significantly; litter weights, number of viable fetuses decreased; number of embryo resorptions increased significantly; number of liveborn F(1a), F(1b) and F(2a) decreased. No macroscopic or microscopic change of any significance was found in the reproductive organs. Significant increases in the incidence of cervical ribs or lumbar ribs in F(2a) pups and significant increases of relative organ weight of testis and epididymis in F(1b) were observed at the 250 mg/kg b.w./day cyadox group. The NOAEL for reproduction/development of cyadox for rats was estimated to be 150 mg/kg diet, which was equivalent to approximately 15 mg/kg b.w./day.

    Topics: Abnormalities, Drug-Induced; Administration, Oral; Analysis of Variance; Animal Feed; Animals; Animals, Newborn; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Epididymis; Female; Fetal Development; Male; Maternal Exposure; No-Observed-Adverse-Effect Level; Organ Size; Pregnancy; Quinoxalines; Rats; Rats, Wistar; Reproduction; Teratogens; Testis

2011
Subchronic oral toxicity study with cyadox in Wistar rats.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2006, Volume: 44, Issue:1

    To investigate the potential subchronic toxicity of cyadox, groups of 15 male and 15 female Wistar rats were fed with diets containing cyadox (0, 50, 150 or 2500 mg/kg) or olaquindox (150 mg/kg), approximately equivalent to cyadox 5, 15, 250 or olaquindox 15 mg/kg b.w./day, for 13 weeks. Five rats/sex/group were sacrificed on days 30, 60 and 90. No test-material-related changes were seen in mortality, clinical signs, hematology, clinical chemistry, organ weight data and macroscopic examinations. Except that body weights of both sexes of the 2500 mg/kg cyadox group were significantly lower than controls beginning after the second week of treatment. Body weights of females of 150 mg/kg olaquindox group were significantly lower than those of the control group at weeks 3 and 4. Other groups were unaffected by treatments. Histopathological observations revealed that 2500 mg/kg cyadox or 150 mg/kg olaquindox induced swelling and fatty degeneration of the hepatocytes and proximal renal tubular epithelial cells. It was for the first time that changes were found in the liver and kidneys of rats fed 2500 mg/kg cyadox. The no-observed-adverse-effect level (NOAEL) of cyadox for rats was estimated to be 150 mg/kg dietary dose level.

    Topics: Administration, Oral; Animals; Anti-Infective Agents; Body Weight; Diet; Dose-Response Relationship, Drug; Epithelial Cells; Female; Hepatocytes; Kidney Tubules, Proximal; Male; No-Observed-Adverse-Effect Level; Quinoxalines; Rats; Rats, Wistar

2006